Journal
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Volume 116, Issue -, Pages 53-61Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcdb.2020.09.011
Keywords
-
Categories
Funding
- Progressive MS Alliance (PMSA) [PA-1604-08492]
- INSERM
- ICM internal fund
- European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Ask authors/readers for more resources
Oligodendrocytes play a crucial role in various diseases, and the use of iPSC technology provides a new approach to studying human oligodendrocytes. The engraftment in animal models can lay the foundation for the development of therapy for demyelinating diseases.
Oligodendrocytes are main targets in demyelinating and dysmyelinating diseases of the central nervous system (CNS), but are also involved in accidental, neurodegenerative and psychiatric disorders. The underlying pathology of these diseases is not fully understood and treatments are still lacking. The recent discovery of the induced pluripotent stem cell (iPSC) technology has open the possibility to address the biology of human oligodendroglial cells both in the dish and in vivo via engraftment in animal models, and paves the way for the development of treatment for myelin disorders. In this review, we make a short overview of the different sources human oligodendroglial cells, and animal models available for pre-clinical cell therapy. We discuss the anatomical and functional benefit of grafted iPSC-progenitors over their brain counterparts, their use in disease modeling and the missing gaps that still prevent to study their biology in the most integrated way, and to translate iPSC-stem cell based therapy to the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available